NASDAQ

Intelligent Bio Solutions Inc. (INBS)

353 Thanks from members

Intelligent Bio Solutions Inc. (INBS) displays mixed financial and clinical progress, featuring 38% fiscal year revenue growth and FDA trial advancements, countered by widening Q2 losses, a going-concern warning, and a depressed $4 million cash position.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →